A randomized, 24 weeks, double-blind, placebo-controlled, parallel-group, multicenter study to assess the efficacy and safety of omalizumab in adult patients with chronic urticaria who exhibit IgE against thyreoperoxidase.
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- Sponsors Novartis
- 20 May 2009 Actual patient number (51) added as reported by ClinicalTrials.gov.
- 20 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.